Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from ChinaBio Today

03:47 EDT 19th October 2018 | BioPortfolio

Here are the most relevant search results for "ChinaBio Today" found in our extensive news archives from over 250 global news sources.

More Information about ChinaBio Today on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ChinaBio Today for you to read. Along with our medical data and news we also list ChinaBio Today Clinical Trials, which are updated daily. BioPortfolio also has a large database of ChinaBio Today Companies for you to search.

Showing News Articles 1–25 of 401 from ChinaBio Today

Friday 19th October 2018

Chi-Med Starts China Trials of Syk Inhibitor in Acute Myeloid Leukemia Patients

Hutchison China MediTech (Chi-Med) has started a China Phase I trial of its novel spleen tyrosine kinase (Syk) inhibitor as a first line treatment in elderly patients with acute myeloid leukemia. The molecule, HMPL-523, will be administered in combination with an approved nucleoside metabolic inhibitor. In September, Chi-Med's lead drug, Elunate® (fruquintinib), was approved in China as a thir...

Singlera Reports Positive Results from Blood-based Diagnostic for Colorectal Cancer

Singlera Genomics, a San Diego-Shanghai diagnostics company, reported its ColonES blood-based colorectal cancer diagnostic showed high sensitivity and specificity in an early China test. In a 1,243 patient study, the ColonES device produced sensitivities of 93% for CRC and 88% for advanced adenomas, with a specificity of 99%. The device is aimed at early diagnosis. Its targeted next-gen sequencing...

Thursday 18th October 2018

Alphamab to Start US Phase I Clinical Trial of HER2 Bispecific Antibody

Suzhou's Alphamab Oncology has received US approval of an IND for KN026, its proprietary HER2 antibody. KN026, the company's lead drug, binds to two separate epitopes on HER2. The candidate started a Phase I China trial earlier this year, and Alphamab said the China trial is proceeding as expected. The company intends to test KN026 in patients with breast, gastric and lung cancer that over-ex...

Wednesday 17th October 2018

CStone Approved to Start US Trials of PD-L1 Candidate

CStone Pharmaceuticals of Suzhou announced US approval of its IND for CS1001, a novel PD-L1 candidate. CStone said the trial approval was the company's first in the US. Developed using Ligand's OMT transgenic animal platform, CS1001 is a fully human, full-length anti-PD-L1 monoclonal antibody, designed to mirror a natural G-type immune globulin 4 (IgG4) human antibody. Because of its design, CSton...

iCell Partners with LineaRx for new CAR-T Manufacturing Platform

iCell Gene Therapeutics, a New York-Zhongshan biopharma, has formed a research partnership for its CD19 CAR-T therapy with LineaRx, a subsidiary of Applied DNA Sciences. LineaRx is developing a non-viral, plasmid-free (NVPF) CAR-T cell manufacturing platform, which it intends to make available to CAR-T developers. The company will transform iCell's CD-19 candidate into LinCART19, a non-viral, plas...

Tuesday 16th October 2018

HiFiBiO Acquires H-Immune, a French Immunotherapy Biotech

HiFiBiO Therapeutics, a Boston, Paris and Shanghai company, has acquired H-Immune, a French biotech with an in vitro immunization-based fully human antibody generation platform (IVI). HiFiBiO has developed its own immunotherapy discovery platform based on single-B-cell screening. It said H-Immune would complement its discovery efforts by identifying first-in-class targets for multiple types of imm...

Innovent to Raise $422 Million in Hong Kong IPO at $2 Billion Valuation

Innovent Biologics of Suzhou plans to raise $422 million in its Hong Kong IPO at a $2 billion valuation, according to multiple media reports. The company, formed in 2011, struck a major $1 billion collaboration with Lilly in 2015. It has a pipeline of 17 candidates (a combination of novel drugs and biosimilars), nine of them in clinical trials and four in Phase III tests. The underwriters will pri...

Sunday 14th October 2018

Week in Review: Biosense Exercises $75 Million Option for China Rights to Neovacs' Lupus Immunotherapy

Deals and Financings  Biosense Global, a New Jersey-Suzhou company, exercised a $75 million option for China rights to a lupus immunotherapy developed by Neovacs of France; Daiichi Sankyo acquired China rights to Penthrox, a fast-acting non-opioid analgesic, from Medical Developments of Australia in a $32.5 million agreement; Lepu Medical Technology of Beijing invested $22 million in New Yor...

Friday 12th October 2018

I-Mab Starts China Trial of Ulcerative Colitis Treatment

I-Mab Biopharma of Shanghai reported the first patient has been dosed in a China Phase II trial of TJ301 in patients with ulcerative colitis. I-Mab in-licensed China rights to the candidate from Switzerland's Ferring in late 2016. TJ301 is a selective IL-6 blocker that allows IL-6 to continue responding to infections, while it moderates the UC immune response. Because of its selecti...

Suzhou's Amor Medical Collaborates with IME to Develop Resorbable Devices

Amor (Suzhou) Medical Sci-Tech, a China-Germany JV, formed a collaboration with IME Medical Electrospinning of Holland to develop a novel resorbable Class III medical device to treat full thickness wounds in oral cavities. Amor was founded in 2017 by a team of China business people who joined with scientists from Germany's Freiburg University to develop regenerative medical products. IME offers na...

Thursday 11th October 2018

BeiGene and MEI Pharma to Test Drug Combination Therapy in B-Cell Malignancies

BeiGene will collaborate with MEI Pharma of San Diego to test MEI's ME-401, a PI3K delta inhibitor, in combination with BeiGene's BTK inhibitor in patients with B-cell malignancies. MEI will amend its ongoing Phase Ib trial to include evaluation of zanubrutinib, BeiGene's BTK inhibitor, in combination with ME-401 in B-cell malignancy patients. The costs of the trial will be shared equally by the t...

Lepu Medical Pays $22 Million to Acquire China Rights for Rgenix Cancer Drugs

Lepu Medical Technology of Beijing invested $22 million in New York-based Rgenix as part of a $40 million Rgenix Series C round. Along with an equity stake, Lepu will have China rights to Rgenix' cancer drug candidates. Rgenix will use the proceeds to support Phase Ib and Phase II clinical trials of its small molecule immunotherapy, RGX-104, plus early development of a molecule that suppresses gas...

Wednesday 10th October 2018

Alphamab Starts Australian Trial of PD-L1/CTLA-4 Bispecific

Alphamab Oncology of Suzhou has started a Phase I clinical trial of its humanized PD-L1/CTLA-4 bispecific antibody in Australia. The company has also been approved to conduct a similar China trial of the candidate, KN046. The company said KN046 is engineered to target the tumor microenvironment, reducing side effects, while its dual target mechanism increases efficacy. In preclinical studies, KN04...

Jinxin Fertility Completes Financing Led by Warburg and CNCB

Jinxin Fertility, a company providing assisted reproductive technology services, received a strategic investment led by Warburg Pincus and CNCB Investment, a CITIC unit. Jinxin ranks second in China in terms of number of reproductive procedures performed. The company has centers in Chengdu, Shenzhen and the US, the latter providing services that are not available in China. Sequoia Capital China an...

Deep Intelligent Pharma Raises $15 Million for AI Drug Development from Sequoia

Deep Intelligent Pharma, a Beijing healthcare AI startup, raised $15 million in a Series B round from Sequoia Capital China. DIP has assembled a team that combines AI engineers with experts in drug R&D to accelerate drug discovery, development and medical affairs using advanced AI and blockchain technologies. In May, DIP completed a $6.6 million series A round from Zhen Fund, which also invest...

Tuesday 9th October 2018

Yisheng Cleared to Start China Phase III Trial of PIKA Rabies Vaccine

Yisheng Biopharma, a Beijing immunomodulatory company, reported the CFDA will allow a Phase III trial of its PIKA® rabies vaccine. Yisheng has completed Phase I and II studies of the vaccine in Singapore and now plans a pivotal Phase III trial in Southeast Asia countries, with enrollment beginning in 2019. The company developed the rabies vaccine using its proprietary toll-like receptor-3 (TLR...

Biosense Acquires China Rights to Immunotherapy in $75 Million Deal

Biosense Global, a New Jersey-Suzhou in-licensing company, exercised a $75 million option for China rights to an active lupus immunotherapy developed by Neovacs, a French biopharma. The exercise of the option follows a successful Phase II trial of the therapeutic vaccine, IFNalpha Kinoid. Biosense will make an undisclosed upfront payment plus milestones. It will also underwrite a China arm of a gl...

Monday 8th October 2018

Daiichi Sankyo in $32.5 Million Deal for China Rights to Australian Non-Opioid Analgesic

Daiichi Sankyo acquired greater China rights to Penthrox, a fast-acting non-opioid analgesic, from Medical Developments of Australia in a $32.5 million agreement. Penthrox, an oral prescription drug known as the green whistle because of its packaging, is used for pain relief in trauma and minor surgical procedures. Daiichi Sankyo will make $15 million in upfront and sales-based milestone payments....

Saturday 6th October 2018

Week in Review: Shanghai Henlius to File for Hong Kong IPO at Valuation of Over $1 Billion

Deals and Financings  Fosun Pharma plans a Hong Kong IPO for Shanghai Henlius Biotech, its antibody JV subsidiary devoted to novel biotech and biosimilar candidates; GO Therapeutics of Boston signed a $195 million licensing deal with Roche to develop cancer antibodies; last year, Shenzhen Salubris acquired China rights to GO products in return for a $5 million investment; Aohua Endoscopy, a ...

Friday 5th October 2018

PharmaBlock Acquires China Manufacturing Plant from Porton Pharma

PharmaBlock Sciences of Nanjing, a CDMO, has acquired a GMP compliant manufacturing facility in China from Porton Pharma. The facility, a three-year-old, 1.5 million square foot plant located in Shangyu, Zhejiang Province, will provide preclinical-, clinical- and commercial- stage manufacturing of intermediates for PharmaBlock clients. It is PharmaBlock's second manufacturing plant. At the new sit...

CANbridge Files NDA for Approval of Breast Cancer Drug in China

CANbridge Pharma of Beijing has filed a New Drug Application in China for Nerlynx® (neratinib) as an adjuvant treatment in patients with early-stage HER2-positive breast cancer, following adjuvant Herceptin therapy. China’s National Medical Products Administration (NMPA) has accepted the filing. CANbridge in-licensed Greater China rights to Nerlynx from Puma Biotech (NSDQ: PBYI) in Janua...

Ping An Good Doctor Joins with CR Sanjiu to Promote OTC and TCM Products

Ping An Good Doctor will partner with China Resources Sanjiu, joining Good Doctor's internet platform with CR Sanjiu's portfolio of OTC and prescription TCM products. Good Doctor includes an internet hospital, an in-house medical team and millions of users. It will promote CR Sanjiu's products, as well as creating user profiles to help manage chronic diseases over the internet, and applying its bi...

Thursday 4th October 2018

CANbridge Files for Approval of Breast Cancer Drug in China

CANbridge Pharma of Beijing has filed a New Drug Application in China for Nerlynx® (neratinib) as an adjuvant treatment in patients with early-stage HER2-positive breast cancer, following adjuvant Herceptin therapy. China’s National Medical Products Administration (NMPA) has accepted the filing. CANbridge in-licensed Greater China rights to Nerlynx from Puma Biotech (NSDQ: PBYI) in Janua...

Cellular Bio Acquires Rights to Solid Tumor Immunotherapy from National Cancer Institute

Cellular Biomedicine has been granted a Patent License for a next-gen neoantigen-reactive tumor infiltrating lymphocyte (TIL) technology from the National Cancer Institute of the US. The License gives CBMG non-exclusive, sub-licensable global rights to develop, manufacture and commercialize TIL technology. Financial details were not disclosed, nor did CMBG explain why the technology is "next-gen."...

Wednesday 3rd October 2018

CANbridge Files to Start Clinical Trials of Breast Cancer Drug in China

CANbridge Pharma of Beijing has filed a New Drug Application in China for Nerlynx® (neratinib) as an adjuvant treatment in patients with early-stage HER2-positive breast cancer, following adjuvant Herceptin therapy. China’s National Medical Products Administration (NMPA) has accepted the filing. CANbridge in-licensed Greater China rights to Nerlynx from Puma Biotech (NSDQ: PBYI) in Janua...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks